Lawrence E. Liberti: search on Z-Library

The world's largest scientific articles store. 70,000,000+ articles for free.

Don't use scam websites

1

Benchmarking health technology assessment agenciesâmethodological challenges and recommendations

Wang, Ting, Lipska, Iga, McAuslane, Neil, Liberti, Lawrence, HÃ¶vels, Anke, Leufkens, Hubert

Journal:

International Journal of Technology Assessment in Health Care

Year:

2020

File:

PDF, 455 KB

2020

2

Factors related to drug approvals: predictors of outcome?

Liberti, Lawrence, Breckenridge, Alasdair, Hoekman, Jarno, McAuslane, Neil, Stolk, Pieter, Leufkens, Hubert

Journal:

Drug Discovery Today

Year:

2017

Language:

english

File:

PDF, 602 KB

english, 2017

3

Accelerated approval of medicines: fit for purpose?

Breckenridge, Alasdair, Liberti, Lawrence

Journal:

Nature Reviews Drug Discovery

Year:

2018

Language:

english

File:

PDF, 106 KB

english, 2018

4

Companiesâ Health Technology Assessment Strategies and Practices in Australia, Canada, England, France, Germany, Italy and Spain: An Industry Metrics Study

Wang, Ting, McAuslane, Neil, Liberti, Lawrence, Gardarsdottir, Helga, Goettsch, Wim, Leufkens, Hubert

Journal:

Frontiers in Pharmacology

Year:

2020

File:

PDF, 1.49 MB

2020

5

Evaluation of commercial ginseng products

Lawrence E. Liberti, Ara Der Marderosian

Journal:

Journal of Pharmaceutical Sciences

Year:

1978

Language:

english

File:

PDF, 386 KB

english, 1978

6

Preparing for Regulatory Review and Reimbursement Decisions

Lawrence E. Liberti,Franz Pichler,Stuart R. Walker

Journal:

Pharmaceutical Medicine

Year:

2009

Language:

english

File:

PDF, 98 KB

english, 2009

7

Standardizing the Benefit-Risk Assessment of New Medicines

Lawrence Liberti,James Neil McAuslane,Stuart Walker

Journal:

Pharmaceutical Medicine

Year:

2011

Language:

english

File:

PDF, 161 KB

english, 2011

8

Accelerating access to new medicines: Current status of facilitated regulatory pathways used by emerging regulatory authorities

Liberti, Lawrence, Breckenridge, Alasdair, Hoekman, Jarno, Leufkens, Hubert, Lumpkin, Murray, McAuslane, Neil, Stolk, Pieter, Zhi, Kaining, Rägo, Lembit

Journal:

Journal of Public Health Policy

Year:

2016

Language:

english

File:

PDF, 181 KB

english, 2016

9

Historical Pharmaceutical Exhibits at PCP&S

Lawrence Liberti, Geraldine Coyle and Ara Der Marderosian

Journal:

Pharmacy in History

Year:

1980

Language:

english

File:

PDF, 738 KB

english, 1980

10

Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland

Allen, Nicola, Walker, Stuart R., Liberti, Lawrence, Salek, Sam

Journal:

Value in Health

Year:

2017

Language:

english

File:

PDF, 1.76 MB

english, 2017

11

The Benefit-Risk Assessment of Medicines

McAuslane, Neil, Leong, James, Liberti, Lawrence, Walker, Stuart

Journal:

Therapeutic Innovation & Regulatory Science

Year:

2017

Language:

english

File:

PDF, 827 KB

english, 2017

12

Building Synergy between Regulatory and HTA Agencies beyond Processes and Procedures—Can We Effectively Align the Evidentiary Requirements? A Survey of Stakeholder Perceptions

Wang, Ting, McAuslane, Neil, Liberti, Lawrence, Leufkens, Hubert, Hövels, Anke

Journal:

Value in Health

Year:

2017

Language:

english

File:

PDF, 1009 KB

english, 2017

13

FDA Facilitated Regulatory Pathways: Visualizing Their Characteristics, Development, and Authorization Timelines

Liberti, Lawrence, Bujar, Magda, Breckenridge, Alasdair, Hoekman, Jarno, McAuslane, Neil, Stolk, Pieter, Leufkens, Hubert

Journal:

Frontiers in Pharmacology

Year:

2017

Language:

english

File:

PDF, 982 KB

english, 2017

14

A Comparison of Reimbursement Recommendations by European HTA Agencies: Is There Opportunity for Further Alignment?

Allen, Nicola, Liberti, Lawrence, Walker, Stuart R., Salek, Sam

Journal:

Frontiers in Pharmacology

Year:

2017

Language:

english

File:

PDF, 2.47 MB

english, 2017

15

The confluence of accelerated regulatory and health technology assessment access pathways

McAuslane, Neil, Liberti, Lawrence, Connelly, Patricia

Journal:

Clinical Pharmacology & Therapeutics

Year:

2018

Language:

english

File:

PDF, 744 KB

english, 2018

16

A Proposed Framework for a Globally Applicable Pragmatic Approach to Using Facilitated Regulatory Pathways

Liberti, Lawrence, McAuslane, Neil, Stolk, Pieter, Breckenridge, Alasdair, Leufkens, Hubert

Journal:

Therapeutic Innovation & Regulatory Science

Year:

2018

File:

PDF, 456 KB

2018

17

VP155 Synchronization Of Regulatory Approval And Health Technology Assessment Recommendation Timing

McAuslane, Neil, Wang, Tina, Liberti, Lawrence

Journal:

International Journal of Technology Assessment in Health Care

Year:

2017

Language:

english

File:

PDF, 568 KB

english, 2017

18

Neurobiological research with suicidal participants: A framework for investigators

Ballard, Elizabeth D., Waldman, Laura, Yarrington, Julia S., Gerlus, Nimesha, Newman, Laura E., Lee, Laura, Sparks, Mary, Liberty, Victoria, Pao, Maryland, Park, Lawrence, Zarate, Carlos A.

Journal:

General Hospital Psychiatry

Year:

2020

File:

PDF, 427 KB

2020

19

A Proposed Framework for a Globally Applicable Pragmatic Approach to Using Facilitated Regulatory Pathways

Liberti, Lawrence, McAuslane, Neil, Stolk, Pieter, Breckenridge, Alasdair, Leufkens, Hubert

Journal:

Therapeutic Innovation & Regulatory Science

Year:

2020

File:

PDF, 509 KB

2020

20

A Baseline Analysis of Regulatory Review Timelines for ANVISA: 2013â2016

Patel, Prisha, Cerqueira, Daniela Marreco, Santos, Gustavo Mendes Lima, de Lima Soares, Renata, Sousa, Varley Dias, Liberti, Lawrence, McAuslane, Neil

Journal:

Therapeutic Innovation & Regulatory Science

Year:

2020

File:

PDF, 984 KB

2020

21

Use of the Certificate for Pharmaceutical Products (CPP) in 18 Maturing Pharmaceutical Markets: Comparing Agency Guidelines with Company Practice

Rodier, CÃ©line, Bujar, Magda, McAuslane, Neil, Patel, Prisha, Liberti, Lawrence

Journal:

Therapeutic Innovation & Regulatory Science

Year:

2020

File:

PDF, 1.53 MB

2020

22

To what degree are review outcomes aligned for new active substances (NASs) between the European Medicines Agency and the US Food and Drug Administration? A comparison based on publicly available information for NASs initially approved in the time period 2014 to 2016

KÃ¼hler, Thomas Christian, Bujar, Magda, McAuslane, Neil, Liberti, Lawrence

Journal:

Year:

2019

File:

PDF, 676 KB

2019